 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H23ClN2O |
| Molar mass | 378.90 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RTI(-4229)-177 (2β-(3-phenylisoxazol-5-yl)-3β-(4-chlorophenyl)tropane,β-CPPIT) is a syntheticstimulant drug from thephenyltropane family, which acts as aDRI with micromolar affinity for theSERT.[1] RTI-177 has an unusually long duration of action of 20 hours or more, substantially longer than the related compoundRTI-336 from which it differs in molecular structure only by the absence of ap-methyl group.[2]
"the nonselectivemonoamine transporter inhibitorRTI-126 and theDAT-selective inhibitorsRTI-150 and RTI-336 both had a faster rate of onset (30 min) and a short duration of action (4h). In contrast, the nonselective monoamine transporter inhibitorRTI-112 had a slower rate of onset (30–60 min) and a longer duration of action (10h). The DAT-selective inhibitorsRTI-171 and RTI-177 also had slower rates of onset (30–120 min), but RTI-171 had a short duration of action (2.5 h) while RTI-177 had a very long duration of action (20 h)."[3]
| RTI | X | R | [3H]CFT | [3H]Nisoxetine | [3H]Paroxetine |
|---|---|---|---|---|---|
| Coc | — | — | 89.1 | 3298 (1986) | 1045 (45) |
| 177 | Cl | phenyl | 1.28 | 504 (304) | 2420 (220) |
| 176 | Me | phenyl | 1.58 | 398 (239) | 5110 (465) |
| 354 | Me | ethyl | 1.62 | 299 (180) | 6400 (582) |
| 336 | Cl | p-cresyl | 4.09 | 1714 (1033) | 5741 (522) |
| 386 | Me | p-anisoyl | 3.93 | 756 (450) | 4027 (380) |
In the Lindsey paper, RTI-177 was wrongly considered to be a dual inhibitor of theNET, although this was later found out to be incorrect.[citation needed]
"In acute toxicity studies in male rats, 3β-(4-chlorophenyl)-2β-[3-(4’-methylphenyl)isoxazol-5-yl]tropane (RTI-336) possessed an LD50 of 180 mg/kg after oral administration, compared with 49 mg/kg for RTI-177 (unpublished results, Howell 2005; Table 9). These results suggested that RTI-336 was a better candidate than RTI-177 for further preclinical development."[2]
Also the potency of theheterocyclic compounds is not as great as would be predicted based onin vitro test results.
